KYTX (Kyverna Therapeutics) Equity-to-Asset : 0.88 (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Kyverna Therapeutics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Kyverna Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2024 was $266.59 Mil. Kyverna Therapeutics's Total Assets for the quarter that ended in Dec. 2024 was $304.65 Mil.

The historical rank and industry rank for Kyverna Therapeutics's Equity-to-Asset or its related term are showing as below:

KYTX' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.75 Med: -0.82 Max: 0.88
Current: 0.88

During the past 4 years, the highest Equity to Asset Ratio of Kyverna Therapeutics was 0.88. The lowest was -1.75. And the median was -0.82.

KYTX's Equity-to-Asset is ranked better than
79.53% of 1505 companies
in the Biotechnology industry
Industry Median: 0.67 vs KYTX: 0.88

Kyverna Therapeutics Equity-to-Asset Historical Data

The historical data trend for Kyverna Therapeutics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyverna Therapeutics Equity-to-Asset Chart

Kyverna Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Equity-to-Asset

-0.54

-1.11

-1.75

0.88

Kyverna Therapeutics Quarterly Data
	Dec21	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Equity-to-Asset	Get a 7-Day Free Trial					-1.75	0.93	0.92	0.89	0.88

Competitive Comparison of Kyverna Therapeutics's Equity-to-Asset

For the Biotechnology subindustry, Kyverna Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kyverna Therapeutics's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kyverna Therapeutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Kyverna Therapeutics's Equity-to-Asset falls into.

Save Embed

;

Save Embed

;

Kyverna Therapeutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Kyverna Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Equity to Asset (A: Dec. 2024 )	=	Total Stockholders Equity	/	Total Assets
	=	266.587	/	304.645
	=

Kyverna Therapeutics's Equity to Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

Equity to Asset (Q: Dec. 2024 )	=	Total Stockholders Equity	/	Total Assets
	=	266.587	/	304.645
	=

Kyverna Therapeutics (NAS:KYTX) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Kyverna Therapeutics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Kyverna Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Kyverna Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kyverna Therapeutics Inc (NAS:KYTX) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

5980 Horton Street, Suite 550, Emeryville, CA, USA, 94608

Website

https://www.kyvernatx.com

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.